Clinical trial
EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus…
NCT00078546 · Baylor College of Medicine, Other · Completed
Key facts
| NCT number | NCT00078546 |
|---|---|
| Title | EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC) |
| Official title | Administration of EBV-Specific Cytotoxic T Lymphocytes Following CD45 Antibody to Patients With EBV Positive Nasopharyngeal Carcinoma |
| Acronym | CLANC |
| Lead sponsor | Baylor College of Medicine, Other |
| Collaborators | The Methodist Hospital Research Institute Center for Cell and Gene Therapy, Baylor College of Medicine |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Nasopharyngeal Cancer, EBV Infections |
| Intervention type | Biological |
| Interventions | EBV specific CTL Infusion, Anti CD45 monoclonal antibody |
| Enrollment | 12 |
| Start date | Sep 1, 2003 |
| Primary completion | Jan 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Mar 2, 2004 |
| Last update posted | Jul 30, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: